Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Social media

BIOGRAPHY

Carlo Rinaldi completed his medical education in 2005 and his residency in adult neurology in 2010 both with distinction at the University of Federico II, Naples, Italy. In 2009 he joined the Neurogenetics Branch at the National Institute of Health (Bethesda, MD, USA) under the supervision of prof. Fischbeck, to work on the mechanisms of pathogenesis of spinal and bulbar muscular atrophy (SBMA or Kennedy's disease) and other genetic diseases of the motor unit and where he also obtained a PhD in Neuroscience with the thesis entitled: 'From Disease Gene Identification to Therapeutic Targets in Neuromuscular Diseases'. In 2015 he joined the lab of prof. Wood at the University of Oxford as a Clinical Research Fellow and in December 2016 was awarded a Stage 2 Wellcome Trust Clinical Research Career Development Fellowship. He is an Honorary Consultant Neurologist at the John Radcliffe Hospital in Oxford and at the National Hospital for Neurology and Neurosurgery in London.

Carlo Rinaldi

MA MD PhD


Professor of Molecular and Translational Neuroscience

  • UKRI MRC Senior Clinical Fellow
  • Honorary Consultant Neurologist
  • Director of Graduate Studies

Research Summary

The overall purpose of my research is to reduce the burden of he­reditary neurological disease. This goal is pursued through three strategic aims: (1) identifi­cation of genes associated with neurological diseases, (2) advancement of the current understanding of the molecular mechanisms of pathogenesis in these diseases, and (3) development of effective treat­ments for hereditary neurological diseases.

For more info, visit the R-lab web page.